Scholarlink

<p>Traumatic osteomyelitis (TO) treatment remains challenging due to biofilm formation and poor antibiotic penetration. We developed poly(lactic-co-glycolic acid) (PLGA) microspheres co-loaded with moxifloxacin/rifampicin (M/R-P) to address these limitations. Key findings: In vitro: The microspheres showed (1) no cytotoxicity (CCK-8 assay; live/dead staining; cytoskeletal staining; SEM visualization), and (2) no inhibition of osteogenic potential (ALP activity).In vivo: M/R-P microspheres significantly reduced MRSA burden ( 8 ± 3 × 10³ CFU/g) compared to debridement-only controls (3143 ± 727 × 10³ CFU/g; <i>p</i> &lt; 0.0001), and near-complete infection resolution (histopathology). Conclusion: These results demonstrate that the M/R-P microspheres possess excellent safety profiles, favorable cytocompatibility, and remarkable antibacterial efficacy. The findings confirm the feasibility of our innovative approach using PLGA as a drug delivery carrier for localized antibiotic therapy in chronic osteomyelitis treatment, achieved through technological optimization for combined antibiotic administration. This provides a novel strategic direction for ultimately overcoming the clinical challenge of traumatic osteomyelitis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual antibiotic PLGA microspheres for the treatment of traumatic osteomyelitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月21日

查看全文
  • Liangguo Si,
  • Wenping Zhang,
  • Haifeng Jiang,
  • Haiqiang Ma,
  • Xu Ma,
  • Peijie Zhao,
  • Huanhuan Sun,
  • Zhipeng Yang,
  • Zewen Qiao

摘要

Traumatic osteomyelitis (TO) treatment remains challenging due to biofilm formation and poor antibiotic penetration. We developed poly(lactic-co-glycolic acid) (PLGA) microspheres co-loaded with moxifloxacin/rifampicin (M/R-P) to address these limitations. Key findings: In vitro: The microspheres showed (1) no cytotoxicity (CCK-8 assay; live/dead staining; cytoskeletal staining; SEM visualization), and (2) no inhibition of osteogenic potential (ALP activity).In vivo: M/R-P microspheres significantly reduced MRSA burden ( 8 ± 3 × 10³ CFU/g) compared to debridement-only controls (3143 ± 727 × 10³ CFU/g; p < 0.0001), and near-complete infection resolution (histopathology). Conclusion: These results demonstrate that the M/R-P microspheres possess excellent safety profiles, favorable cytocompatibility, and remarkable antibacterial efficacy. The findings confirm the feasibility of our innovative approach using PLGA as a drug delivery carrier for localized antibiotic therapy in chronic osteomyelitis treatment, achieved through technological optimization for combined antibiotic administration. This provides a novel strategic direction for ultimately overcoming the clinical challenge of traumatic osteomyelitis.